Domov › Sklerodermia › New York
Klinické štúdie Sklerodermia v štáte New York
11 štúdií pre Sklerodermia hľadá účastníkov v zariadeniach v štáte New York.
Mestá v štáte New York
Oficiálny text štúdie (anglicky)
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
- Hospital for Special Surgery, New York
- Icahn School of Medicine at Mount Sinai, New York
- Columbia University Medical Center-New York Presbyterian Hospital, New York
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 30. 9. 2026 · NCT07497087Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- NYU Langone Hospital - Long Island, Mineola
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- a 1 ďalších
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 23. 9. 2026 · NCT03816345A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- Icahn School of Medicine at Mount Sinai, New York
Prebieha náborFáza 1
Vek 18 až 74 · Všetky pohlavia · Aktualizované 10. 9. 2026 · NCT07085104A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
- GSK Investigational Site, New York
- GSK Investigational Site, New York
Prebieha náborFáza 2/3
Vek 18 a viac · Všetky pohlavia · Aktualizované 8. 9. 2026 · NCT05878717Platform Clinical Study for Conquering Scleroderma
- Northwell Health, Great Neck
- Hospital for Special Surgery, New York
- Columbia University Medical Center, New York
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 18. 8. 2026 · NCT06195072RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
- Columbia University Irving Medical Center, New York
- University of Rochester, Rochester
Prebieha náborFáza 2/3
Vek 18 až 75 · Všetky pohlavia · Aktualizované 17. 8. 2026 · NCT06328777A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
- Nkarta Investigational Site, New York
- Nkarta Investigational Site, Stony Brook
- Nkarta Investigational Site, Syracuse
Prebieha náborFáza 1/2
Vek 18 až 75 · Všetky pohlavia · Aktualizované 7. 8. 2026 · NCT06733935A Study of AZD0120 in Autoimmune Diseases
- Research Site, New York
Prebieha náborFáza 1
Vek 18 až 75 · Všetky pohlavia · Aktualizované 28. 7. 2026 · NCT07295847A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
- Montefiore Medical Center, New York
Prebieha náborFáza 1
Vek 12 až 70 · Všetky pohlavia · Aktualizované 22. 5. 2026 · NCT06308978Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis
- Hospital for Special Surgery, New York
Prebieha náborFáza 2
Vek 18 až 80 · Všetky pohlavia · Aktualizované 27. 3. 2026 · NCT03844061Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
- aTyr Investigative Site, New York
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 7. 5. 2025 · NCT05892614Z ClinicalTrials.gov, dáta načítané 4. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.